About this trial
The goal of this intervention study is to examine the impact of pharmacist-led interventions in psychiatric patients initiating second-generation antipsychotic treatment. The primary purpose is to assess the impact of intervention on antipsychotic induced metabolic outcomes, such as weight gain and other cardiometabolic risk markers, in patients aged 18 to 60 years who have been diagnosed with chronic mental disorder. Participants will be assigned to either the intervention or the control group. The intervention group will receive educational interventions from the pharmacist at baseline, after 4 weeks, 8 weeks, and 12 weeks along with the standard therapy prescribed by the psychiatrist. On the other hand, the control group will receive only the standard therapy with no intervention from the pharmacist.
Eligibility criteria
Qualifiers
Adults aged 18-60 years.
Diagnosed with schizophrenia, bipolar disorder, or major depressive disorder.
Currently prescribed a second-generation antipsychotic for < 2 months.
Willing to participate in lifestyle and counseling sessions.
Disqualifiers
Patients with severe medical comorbidities.
Pregnant or breastfeeding women.
Patients receiving only first-generation antipsychotics.
Patients taking more than three antipsychotics.
Trial design
Treatments tested in this trial
- Pharmacist monitoring and counseling to prevent or delay metabolic syndrome
Treatment groups
Sponsors and collaborators
University of Lahore
Lead sponsor
Punjab Institute of Mental Health
Collaborator